We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00294502
First Posted: February 22, 2006
Last Update Posted: February 22, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Henry Ford Health System
  Purpose
To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment (“antibiotic lock solution - ALS”) to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.

Condition Intervention Phase
ESRD Drug: Gentamycin/citrate, Minocycline/EDTA Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Henry Ford Health System:

Primary Outcome Measures:
  • Incidence of symptomatic CRB

Estimated Enrollment: 120
Study Start Date: September 2003
Estimated Study Completion Date: May 2004
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • ESRD patients with tunnelled catheters

Exclusion Criteria:

  • patients on IV abx for infections, patients who have AV graft, AV fistulas
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00294502


Locations
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Investigators
Principal Investigator: Antanole Bearabe, MD Henry Ford Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00294502     History of Changes
Other Study ID Numbers: 3008
First Submitted: February 21, 2006
First Posted: February 22, 2006
Last Update Posted: February 22, 2006
Last Verified: September 2003

Additional relevant MeSH terms:
Minocycline
Gentamicins
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action